Benzinga | Sep 9, 2021 06:57AM EDT

Stifel Downgrades Vertex Pharmaceuticals to Hold, Lowers Price Target to $213

Stifel analyst Paul Matteis downgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Buy to Hold and lowers the price target from $244 to $213.